Syngene acquires facility from Stelis Biopharma for ₹ 702 cr
Syngene International, a subsidiary of Biocon Ltd., has decided to acquire a Unit 3 biologics manufacturing facility in Bengaluru from Stelis Biopharma Limited (SBL) on a slump sale basis for a gross value of ₹702 crore.The deal, which is…